Central Kentucky Research Associates Inc is a multispecialty
clinical research site with offices in Lexington and Mt. Sterling,
Kentucky. The ability to recruit evaluable patients rapidly and
produce high-quality study results in a timely manner has
earned Central Kentucky Research Associates, Inc. (CKRA) a
sterling reputation as one of the nation's leading, independent
clinical drug research facilities. This is affirmed by the fact that
the company, which ranks in the top 10 percent of the nation's
clinical trial sites in subject evaluability, has conducted trials
(Phases1 through IV) for every major drug company in the U.S.
and many in Europe and Japan.

Central Kentucky Research Associates (CKRA) makes it
possible for people to participate in clinical trials that can
change the face of medicine. Founded in 1991 by Deborah
Dyer, RN, BSN and Jacqueline Smith, RN, BSN, CCRC,
CKRA was Kentucky's first independent clinical drug research
facility. CKRA is also one of the few such facilities in the
nation that is owned and operated by women who are not
physicians.

CKRA has conducted over 350 Phase II, III, and IV clinical
trials in the areas of Allergy, Cardiology, Dermatology,
Endocrine/Metabolism , Gastroenterology Infectious Diseases,
Musculoskeletal, Neurology Pain Management, Pediatrics,
Respiratory, Urology Women's Health.
Patients are recruited through the company’s extensive database
and through advertising mediums such as television, radio,
and print.

CKRA operates as an outpatient facility with access to inpatient
care. Our facility offers the following amenities:

• Completion of over 10 Phase I pre-clinical kinetics trials
• Computerized study management tracking system
• Comfortable waiting room with snack bar
• Remote and internet data entry experience
• Monitor area with phone, fax, copier, shredder and dedicated computer lines
• Locked CRF library
• Standardized and locked Regulatory Files
• On-site overnight facility
• On-site short term storage facility
• Off-site long term storage facility
• Initial Regulatory Packets completed within 48 hours of receipt
• Contact/Budget negotiations completed within 48 hours of receipt
• Capability to preform clinical trials using scheduled 1 drugs